Arrowhead Research Corp Down Big On Disappointing Hepatitis B Drug Data

October 8, 2014 11:41 AM | 1 min read | Make a Comment

Shares of

Arrowhead Research CorpARWR

are down sharply following tweets by Adam Feuerstein pointing to disappointing data on its Hepatitis B drug.

Shares of Arrowhead Research Corp have been halted three times Wednesday, last trading at $5.76, down 54.4 percent.

Posted In: News Movers Adam Feuerstein

Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.